樊 艳



多西他赛联合表柔比星新辅助化疗治疗局部晚期乳腺癌疗效观察

樊 艳

【摘要】目的 研究多西他赛（DOC）联合表柔比星（EPI）新辅助化疗治疗局部晚期乳腺癌（LABC）的临床疗效。方法 选择2010年2月～2014年8月我院84例LABC患者作为研究对象，根据化疗方案的不同分为两组，其中观察组48例行DOC联合EPI化疗，对照组36例行传统EPI + 5-氟尿嘧啶（5-FU）+环磷酰胺（CTX）化疗方案，化疗结束后，随访观察1年，比较两组化疗效果及毒副作用。结果 观察组总有效率和1年期生存率分别为92．75%和25．00%，高于对照组的77．78%和8．33%，差异有统计学意义（P＜0．05）。观察组骨髓抑制、胃肠道反应、静脉炎及脱发等毒副作用发生率低于对照组，差异有统计学意义（P＜0．05）。结论 DOC联合EPI新辅助化疗能改善局部晚期乳腺癌患者近期疗效，提高远期生存率，减少毒副作用的发生。

【关键词】晚期乳腺癌；多西他赛；表柔比星；临床疗效；毒副作用

Objective To investigate the effect of docetaxel（DOC）combined with Epirubicin（EPI）neoadjuvant chemotherapy in treatment of locally advanced breast cancer（LABC）． Methods In our hospital，from February 2010 to August 2014，84 patients with LABC patients as the research object，according to different chemotherapy regimens for the two groups． The observation group，48 cases using DOC and EPI for combination

chemotherapy and control group of 36 cases were treated by traditional EPI5- fluorouracil（5-FU）plus cyclophosphamide （CTX） chemotherapy．After chemotherapy，all patients were followed up for 1 year，compared two groups of chemotherapy effect and toxic and side effect． Results The total effective rate and 1 year survival rate of the observation group were 92．75% and 25．00%，respectively，significantly higher than that of the control group （77．78% and 8．33%），the difference was statistically significant（P＜0．05）． In the observation group，the incidence of bone marrow suppression，gastrointestinal reaction，phlebitis and hair loss and other toxic side effects were significantly lower than that of the control group，the difference was statistically significant （P＜0．05）． Conclusion DOC combined with EPI neoadjuvant chemotherapy can significantly improve the short-term efficacy of locally advanced breast cancer patients，improve the long-term survival rate and reduce the toxic and side effects．

【Key words】Advanced breast cancer，Docetaxel，Epirubicin，Clinical curative effect，Side effect

LABC是指肿瘤直径＞5 cm，已侵袭对侧乳房内侧象限或皮肤胸壁而尚未发生远处转移的恶性肿瘤。有资料显示，乳腺癌有年轻化趋势，且发病率逐年上升［1］。单纯手术治疗复发率高，预后多不理想，因此多采用手术加用放化疗治疗的方法，但传统放化疗多诱发骨髓抑制、放射性肺炎、皮肤溃疡等严重并发症。新辅助化疗作为一种针对非转移性肿瘤的新型辅助化疗方案，在抑制肿瘤远处转移、降低并发症方面获得较为满意的临床疗效。我院选取2010年2月～2014年8月84例LABC患者作为研究对象，探讨DOC联合EPI新辅助化疗方案在局部晚期乳腺癌中的应用价值，现将结果介绍如下，供临床参考。……